Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
Landsburg, Daniel J
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. [electronic resource] - Blood advances 01 2019 - 132-135 p. digital
Publication Type: Journal Article
2473-9537
10.1182/bloodadvances.2018026401 doi
Adenine--analogs & derivatives
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--administration & dosage
Biomarkers, Tumor
Drug Resistance, Neoplasm
Female
Genes, bcl-2
Genes, myc
Humans
Lymphoma, B-Cell--diagnosis
Male
Middle Aged
Piperidines
Prognosis
Protein Kinase Inhibitors--administration & dosage
Pyrazoles--administration & dosage
Pyrimidines--administration & dosage
Recurrence
Retreatment
Treatment Outcome
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. [electronic resource] - Blood advances 01 2019 - 132-135 p. digital
Publication Type: Journal Article
2473-9537
10.1182/bloodadvances.2018026401 doi
Adenine--analogs & derivatives
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--administration & dosage
Biomarkers, Tumor
Drug Resistance, Neoplasm
Female
Genes, bcl-2
Genes, myc
Humans
Lymphoma, B-Cell--diagnosis
Male
Middle Aged
Piperidines
Prognosis
Protein Kinase Inhibitors--administration & dosage
Pyrazoles--administration & dosage
Pyrimidines--administration & dosage
Recurrence
Retreatment
Treatment Outcome